

A

ABAZOVIC B.

Process Analytical Technology – PAT – 3, 26

ALOECORP

Nature couldn't do much to improve *Aloe vera*. So we did it – in *Nutra Buyers Guide*, 24

ANTUNES A.M.S.

Initiative prioritization for innovation in the Brazilian pharmaceutical industry: A proposal using multicriteria – 9, 26

ANWAR J.

Development, labelling and clinical evaluation of ^{99m}Tc-ciprofloxacin in diagnosis of orthopedic infections: Comparative study with ^{99m}Tc-methylene diphosphonate (^{99m}Tc-MDP) scintigraphy – 3, 42

Synthesis, characterization, radiolabelling and biodistribution of chemotactic peptide ^{99m}Tc-cysteine-fMLF as a potential renal infection imaging agent – 4, 46

ASGHAR S.

Development, labelling and clinical evaluation of ^{99m}Tc-ciprofloxacin in diagnosis of orthopedic infections: Comparative study with ^{99m}Tc-methylene diphosphonate (^{99m}Tc-MDP) scintigraphy – 3, 42

Synthesis, characterization, radiolabelling and biodistribution of chemotactic peptide ^{99m}Tc-cysteine-fMLF as a potential renal infection imaging agent – 4, 46

ASPIRAS

Medtech Founders benefit from know-how of Aspiras – 1-2, 32

B

BATH J.

Making the strategic move to outsource packaging then choosing the right partner – 11-12, 16

BONNEFILLE M.

Taste analysis of oral formulations using an electronic tongue – 4, 26

BORSCHIVER S.

Technological monitoring of glutathione, the master antioxidant – 5, 2

Initiative prioritization for innovation in the Brazilian pharmaceutical industry: A proposal using multicriteria – 9, 26

BRAJSA K.

High-throughput antifungal screening: Method optimization – 5, 14

BRÜCHERT W.

Finding the needle in the haystack – Coupling technologies with mass spectrometry decipher complex chemistry – 10, 46

BRUNO J.

The market in China – An interesting challenge – 4, 10

BUSKER E.

Finding the needle in the haystack – Coupling technologies with mass spectrometry decipher complex chemistry – 10, 46

C

CHEN H.-M.

Echinacea: Immune boosting or

immuno-suppressing? – 3, 14

CHUANG P.-H.

Echinacea: Immune boosting or immuno-suppressing? – 3, 14

CIMPAN G.

Measuring solubility - A challenge – 11-12, 2

COMER J.

Measuring solubility - A challenge – 11-12, 2

CONTO A.

The business implications related to REACH – 1-2, 6

The evolution of the Safety Data Sheet within the European regulatory legislation – From the past to the REACH format – 10, 13

CORNETT M.

Improved liquid handling for MALDI plate spotting – 1-2, 10

CREABILIS

CREABILIS therapeutics receives MHRA authorization to carry out Phase I Clinical trial in the UK for topical CT327 – 7-8, 26

CRUZ E.P.

Initiative prioritization for innovation in the Brazilian pharmaceutical industry: A proposal using multicriteria – 9, 26

D

DAMANI M.

Biopathways, new targets, new opportunities in discovery research – 1-2, 48

DELOITTE TOUCHE TOHMATSU

The future of the life sciences industries: Strategies for success in 2015 – 7-8, 13; and in *The Worldwide PharmaChem Directory*, 2

DIXON N.

Assessing the risk of electrostatic activity in fluids – 6, 11

DONG G.-C.

Echinacea: Immune boosting or immuno-suppressing? – 3, 14

DUDEK N.L.

Peptide based therapies for diabetes – 3, 34

E

EACHUS A.C.

The pharmaceutical industry in 2007 – 4, 5

ELSMORE R.

Biocides under the BPD – 9, 18
REACH – What should I be doing now? – 10, 6

ENDOTHERM GmbH

Outsourcing of medicinal chemistry in the drug discovery process faces CRO's and pharmaceutical companies with challenges – 7-8, 6

F

FLUOROUS TECHNOLOGIES

Fluorous Mitsunobu aids research for potential antitubercular agent – 5, 34
Organocatalysis with a fluororous tag – 5, 34

233rd ACS National Meeting – 5, 35

Oligonucleotide purification and fluororous – A perfect match – 5, 35

FORREST M.

Echinacea: Immune boosting or immuno-suppressing? – 3, 14

FRITZSCHE H.B.

Personal hand and arm protection to -160°C – Keep CRYO GLOVES® readily accessible for the secure handling of liquid nitrogen – 3, 30

FROST & SULLIVAN

Continued drug counterfeiting creates significant scope for implementation of RFID in European pharmaceutical markets – 1-2, 28

Innovative product development to stimulate European sleep diagnostic and associated data management systems market – 1-2, 28

Increased funding for life sciences and strong industrial partnerships crucial to develop knowledge-based economy in Europe – 1-2, 29

Increased funding and developing regulatory framework provide impetus to stem cell therapeutics market – 4, 53

Rising pharmaceutical expenditures and an ageing population propel growth of the European generics market – 4, 53

Affordable, innovative and effective solutions to drive European autoimmune diseases therapeutics market – 4, 54

Demonstrating value created by *in silico* solutions to help maximise virtual screening opportunities in drug discovery – 4, 54

Home healthcare – A solution to tackle rising healthcare costs – 6, 22

Growing interest in personal health records boosts emergent market – 6, 23

European water and wastewater disinfection systems market benefits from rising water quality concerns – 6, 23

Absence of European legislation mandating the use of sharps safety devices will motivate manufacturers to explore growth potential of African markets – 7-8, 9

Growing demand for advanced data handling tools in drug discovery creates growth potential for bioinformatics – 7-8, 9

Drug discovery research takes a leap forward with increasing adoption of electronic lab notebooks – 7-8, 10

Growing demand for inexpensive, effective drugs and continuing patent expiries provide growth prospects for the European generics market – 7-8, 11

Growing emphasis on preventive medicine driving the growth of the European personalised medicine and pharmacogenomics market – 9, 10
Stem cells' differentiation capabilities open research avenues to formulate new and alternative therapies – 9, 10

Automobile sector provides sustainable growth opportunities for electronic chemicals in Europe – 10, 51

Focus on technology and process economics key to the growth of the global nanocomposites market – 10, 51

New mechanisms to treat sleep disorders add vibrancy to the sleep pharmaceuticals arena – 10, 52
 European markets for enzymes in industrial applications – 11-12, 40
 Extensive proteomics research strengthens the uptake for protein purification kits in Europe – 11-12, 40

G

GALIC T.
 High-throughput antifungal screening: Method optimization – 5, 14

GERRITSEN-EBBEN R.
 Health and safety during use of biocidal products: Assessing exposure and preventing / control risks – 9, 13

GROS P.
 Trimethylsilylmethyl lithium: A selective base for metallation of pyridines – 10, 20

H

HEPNER L.
 China as a source for food and pharmaceutical ingredients – The flipside – 4, 14

HERR R.J.
 Tetrazoles as carboxylic acid bioisosteres in drug discovery – 4, 21

HERRAULT A.
 Improved liquid handling for MALDI plate spotting – 1-2, 10

HERZOG P.
 Facilitating open innovation: Idea brokers in the chemical industry – 3, 10

HUNTER C.
 Bridging the gap between biomarker discovery and validation – 7-8, 27

I

INDENA
 A green light to start production of semisynthetic paclitaxel – 7-8, 15
 Indena communication is acclaimed by the Italian Society of Chemistry and Cosmetology – 11-12, 34

IPEC EUROPE
 Excipients crucial for the future of medicines – 3, 39

J

JAVED M.
 Development, labelling and clinical evaluation of ^{99m}Tc-ciprofloxacin in diagnosis of orthopedic infections: Comparative study with ^{99m}Tc-methylene diphosphonate (^{99m}Tc-MDP) scintigraphy – 3, 42
 Synthesis, characterization, radiolabelling and biodistribution of chemotactic peptide ^{99m}Tc-cysteine-fMLF as a potential renal infection imaging agent – 4, 46

JAYARAMAN K.
 Free trade beyond TRIPS - An insight – 11-12, 29

JELIC D.
 High-throughput antifungal screening: Method optimization – 5, 14

K

KADYROV R.
 Optimal coupling of chemical building blocks – 10, 30

KARAU A.
 Conclusion of the Proferm Project House – Biotechnology platform successfully expanded – 6, 26

KELNERIC Z.
 High-throughput antifungal screening: Method optimization – 5, 14

KHAN A.U.
 Development, labelling and clinical evaluation of ^{99m}Tc-ciprofloxacin in diagnosis of orthopedic infections: Comparative study with ^{99m}Tc-methylene diphosphonate (^{99m}Tc-MDP) scintigraphy – 3, 42

Synthesis, characterization, radiolabelling and biodistribution of chemotactic peptide ^{99m}Tc-cysteine-fMLF as a potential renal infection imaging agent – 4, 46

KHAN I.U.
 Development, labelling and clinical evaluation of ^{99m}Tc-ciprofloxacin in diagnosis of orthopedic infections: Comparative study with ^{99m}Tc-methylene diphosphonate (^{99m}Tc-MDP) scintigraphy – 3, 42

Synthesis, characterization, radiolabelling and biodistribution of chemotactic peptide ^{99m}Tc-cysteine-fMLF as a potential renal infection imaging agent – 4, 46

KOULOURIS A.
 The role of process simulation and scheduling tools in the development and commercialization of pharmaceutical products – 1-2, 14

L

LANDIM A.B.
 Technological monitoring of glutathione, the master antioxidant – 5, 2

LI D.H.
 Peptides as antigens – 6, 2

LIDSTRÖM K.-O.
 How to make biocatalytic processes for production of chiral amines more profitable and productive – 9, 5

LODYGA-CHRUSCINSKA E.
 Investigation of pharmaceutical polymorphs – Most common approach – 11-12, 8

M

MAJEED M.
 Free trade beyond TRIPS - An insight – 11-12, 29

MARSIC N.
 High-throughput antifungal screening: Method optimization – 5, 14

MARTINEAU B.
 Nucleic acid testing products – 6, 16

MARUOKA K.
 Highly practical amino acid synthesis with designer chiral phase transfer catalysts – 9, 33

MERIANO E.
 The business implications related to

REACH – 1-2, 6

The evolution of the Safety Data Sheet within the European regulatory legislation – From the past to the REACH format – 10, 13

METZ F.
 Growing the fluoroaliphatic tree: Radical halotrifluoromethylation of alkenes – 4, 34

MÜLLER A.
 Finding the needle in the haystack – Coupling technologies with mass spectrometry decipher complex chemistry – 10, 46

MÜLLER N.
 Synthesis of pyrazoles as intermediates for fine chemicals – 10, 25

N

NAEEM M.
 Development, labelling and clinical evaluation of ^{99m}Tc-ciprofloxacin in diagnosis of orthopedic infections: Comparative study with ^{99m}Tc-methylene diphosphonate (^{99m}Tc-MDP) scintigraphy – 3, 42
 Synthesis, characterization, radiolabelling and biodistribution of chemotactic peptide ^{99m}Tc-cysteine-fMLF as a potential renal infection imaging agent – 4, 46

NASEER H.
 Development, labelling and clinical evaluation of ^{99m}Tc-ciprofloxacin in diagnosis of orthopedic infections: Comparative study with ^{99m}Tc-methylene diphosphonate (^{99m}Tc-MDP) scintigraphy – 3, 42
 Synthesis, characterization, radiolabelling and biodistribution of chemotactic peptide ^{99m}Tc-cysteine-fMLF as a potential renal infection imaging agent – 4, 46

NIEDERGASSE B.
 Facilitating open innovation: Idea brokers in the chemical industry – 3, 10

NINK F.
 Trends and innovative solutions in encapsulating liquid products – 9, 38

P

PALMESE M.L.
 US patent law from a litigation perspective – 6, 33

PAPAVASILEIOU V.
 The role of process simulation and scheduling tools in the development and commercialization of pharmaceutical products – 1-2, 14

PAULY C.
 When time is the key factor – External project consultants as development service integrators – 1-2, 32

PETRIDES D.
 The role of process simulation and scheduling tools in the development and commercialization of pharmaceutical products – 1-2, 14

PISTOLESI R.
 The new European Patent Convention: How might it affect the pharmaceutical industry? – 11-12, 25

PO C.L.
 The use of FRET technology for drug

discovery – 4, 30
Peptides as antigens – 6, 2

PORA H.
Efficient plasmid purification strategies – Simplifying scale-up of gene therapy and DNA vaccines – 3, 6

PURCELL A.W.
Peptide based therapies for diabetes – 3, 34

Q

QURESHY A.
Synthesis, characterization, radiolabelling and biodistribution of chemotactic peptide ^{99m}Tc-cysteine-fMLF as a potential renal infection imaging agent – 4, 46

R

RADOSEVIC D.
High-throughput antifungal screening: Method optimization – 5, 14

RAYSBERG N.
Monitoring matrix metalloproteinases activity using FRET peptide substrates and assay kits – 10, 42

ROCHE DIAGNOSTICS
Roche's Genome Sequencer 20 enters the African continent: First system installation at Inqaba Biotec's sequencing facility in South Africa – 3, 32

German infection center Riems Island now using Genome Sequencer 20 System from Roche – 5, 30

Roche Diagnostics and FIND sign agreement of collaboration in diagnostics for poverty-related diseases – 5, 30

New from Roche: The LightCycler® 480 High Resolution Melting Master for gene scanning – 5, 30

454 Life Sciences becomes a member of the Roche Group – 7-8, 16

Roche acquires NimbleGen to gain entry into high-growth research microarray market – 7-8, 16

A stake in the ground of protein expression: Roche Diagnostics and Eppendorf working together – 9, 30

Roche Applied Science and 454 Life Sciences improve the Genome Sequencer FLX workflow and help reduce instrument run costs – 10, 34

Researchers identify virus possibly responsible for declining honeybee population using 454 sequencing technology from Roche – 11-12, 35

454 Sequencing™: *Science* paper describes a novel, highly efficient method of sequencing ancient DNA, and sequences the mitochondria of ten individual mammoths to prove it – 11-12, 35

The Human Genome Sequencing Center at Baylor College of Medicine increases fleet of Roche Genome Sequencer FLX systems to ten instruments – 11-12, 36

A life sciences renaissance: 100th peer-reviewed publication enabled by 454 Sequencing – 11-12, 37

The Max Planck Institute in Leipzig acquires second Genome Sequencing FLX™ system – 11-12, 37

Roche and ACEA enter exclusive worldwide agreement – 11-12, 38

ROPELLA GROUP
Groundbreaking ceremony for the Ropella Group New International Headquarters – 11-12, 19

ROPELLA P.
Recruiting for retention – 1-2, 2
Watch out for Eddie Haskell – 3, 2
Take charge of your career – 4, 2
Courting the superstar candidate – 5, 8
Do you need workforce planning – 6, 7

The competitive advantage – 7-8, 2
Improve retention by being a better manager – 9, 2

Aligning employees with strategy – 10, 2

How to deal with "Workplace Stress" – 11-12, 22

Executing more effective performance reviews – in *Nutra Buyers Guide*, 2

S

SAINT-JALMES L.
Growing the fluoroaliphatic tree: Radical halotrifluoromethylation of alkenes – 4, 34

SALTIGO
Saltigo: Go for first class service – Interview to W. STAHL and A. GIDNER – 3, 18

SARAF A.M.
Contract research organisations – 5, 38

SARAF N.M.
Contract research organisations – 5, 38

SCHLEICH W.
Finding the needle in the haystack – Coupling technologies with mass spectrometry decipher complex chemistry – 10, 46

SCHOMMER C.
Sourcing challenges under REACH – 5, 41

SEIDELMANN O.
Pre-clinical chiral chemistry: A special field for outsourcing? – 5, 19

SILETTI C.
The role of process simulation and scheduling tools in the development and commercialization of pharmaceutical products – 1-2, 14

SWINSON J.
Fully functional fluorine – 4, 38

SYKULA A.
Investigation of pharmaceutical polymorphs – Most common approach – 11-12, 8

T

TALAMI S.
Will the pharmaceutical fine chemical industry rise to the new challenge? – 10, 37

THERMO FISHER SCIENTIFIC
Service without boundaries – Interview to S. VERHEYDEN – 9, 22

Thermo Fisher Scientific to showcase Fine and Custom Chemistry Services at CPhI Worldwide 2007 in Milan – 9, 31

THIBODEAU L.
A quick tutorial on the flow behavior of spray coatings for pharmaceuticals – 4, 18

U

URATA K.
A perspective on the potential of artificial lipids for carbon nano-tubes (CNTs) surface modification – 7-8, 20

V

VAN GAALEN S.
The benefits of UV disinfection in the pharmaceutical industry – 3, 22

VAN HEMMEN J.J.
Health and safety during use of biocidal products: Assessing exposure and preventing / control risks – 9, 13

VEHABOVIC M.
Global crisis: Counterfeit and substandard drugs – 1-2, 40
Process Analytical Technology – PAT – 3, 26

VENZAGO C.
Finding the needle in the haystack – Coupling technologies with mass spectrometry decipher complex chemistry – 10, 46

VERBANAC D.
High-throughput antifungal screening: Method optimization – 5, 14

VIANI L.
The business implications related to REACH – 1-2, 6
The evolution of the Safety Data Sheet within the European regulatory legislation – From the past to the REACH format – 10, 13

W

WANG J.
China's price cap policy for pharmaceuticals – 1-2, 23

WOLTERMANN C.J.
Trimethylsilylmethyl lithium: A selective base for metallation of pyridines – 10, 20

Y

YANIK G.W.
HPLC/SFC lab automation – 5, 25

YOUNIS N.
Development, labelling and clinical evaluation of ^{99m}Tc-ciprofloxacin in diagnosis of orthopedic infections: Comparative study with ^{99m}Tc-methylene diphosphonate (^{99m}Tc-MDP) scintigraphy – 3, 42

Z

ZAKRZEWSKI M.
Investigation of pharmaceutical polymorphs – Most common approach – 11-12, 8

ZHUANG S.
Improved liquid handling for MALDI plate spotting – 1-2, 10

ZYCH A.J.
Tetrazoles as carboxylic acid bioisosteres in drug discovery – 4, 21